Are Wall Street Analysts Bullish on Boston Scientific Stock?

Marlborough, Massachusetts-based Boston Scientific Corporation (BSX) is a global medical technology company that develops, manufactures, and markets minimally invasive medical devices. With a market capitalization of approximately $60.8 billion, the company provides innovative solutions across cardiovascular, electrophysiology, endoscopy, urology, neuromodulation, and other medical specialties, serving healthcare providers and patients in more than 120 countries.

Shares of this medtech giant have significantly underperformed the broader market over the past year. BSX has declined 56% during this period, while the broader S&P 500 Index ($SPX) has rallied nearly 10.3%. Likewise, the stock is down 53.5% year-to-date, trailing the index's 10.2% gain over the same period.

Narrowing the comparison, BSX has also underperformed the iShares U.S. Medical Devices ETF (IHI), which has declined 6.1% over the past year. The stock has continued to trail the ETF on a year-to-date basis, with IHI down 9.1%.

On Oct. 28, Boston Scientific reported its Q3 2026 earnings, sending shares down 5.8% on the same day. Net sales increased 1.5% year over year to $5.14 billion, with growth across both Cardiovascular and MedSurg, which rose 1.9% and marginally, respectively. Geographically, LACA led with 16% reported sales growth, followed by 4.4% growth in EMEA, while APAC sales declined marginally. Adjusted EPS decreased 2.7% to $0.73 from the prior-year quarter.

Boston Scientific lowered its full-year 2026 guidance, now expecting reported net sales growth of approximately 4.3% and organic growth of 3.8%, compared with its previous reported sales growth outlook of 5.5% to 6.5%. It also reduced its adjusted EPS guidance to $3.16 to $3.18 from $3.28 to $3.32. For the fourth quarter, the company expects reported and organic sales to decline 1% to 3% year over year and adjusted EPS of $0.77 to $0.79. During the quarter, Boston Scientific also commenced enrollment in the Elite AF clinical trial and received FDA clearances for two StoneSmart technologies and an expanded size offering of its SEISMIQ peripheral catheter.

For the current fiscal year, ending in December 2026, analysts expect BSX’s diluted EPS to increase 3.6% to $3.17. The company has met or exceeded Wall Street’s consensus EPS estimates in each of the past four quarters.

Among the 30 analysts covering BSX stock, the consensus is a “Moderate Buy.” That's based on 15 "Strong Buys," four "Moderate Buys," 10 "Holds," and one "Strong Sell."

BSX’s consensus is more bearish than it was two months ago, when the stock had a "Strong Buy" rating.

On Oct. 30, 2026, TD Cowen analyst Josh Jennings downgraded Boston Scientific to a “Hold” rating and lowered his price target to $46 from $56.

The mean price target of $49.77 represents a 12.3% premium to BSX’s current price levels. The Street-high price target of $60 suggests an ambitious upside potential of 35.4%.

On the date of publication, Abhishek Bhuyan did not directly have a position in any of the securities mentioned in this article. All information and data in this article is solely for informational purposes. For more information please view the Barchart Disclosure Policy here.